Veradermics (MANE) Stock Overview

Operates as a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions. More details

MANE fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Has less than 1 year of cash runway

Shares are highly illiquid

Makes less than USD$1m in revenue ($0)

MANE Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Unicycive Therapeutics

Looking to be second time lucky with a game-changing new product

Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more

1.2k

US$21.53

68.9% undervalued

stuart_roberts's Fair Value

Profit Margin

20%

Future PE

27x

Price in 2030

US$34.67

Veradermics, Incorporated Competitors

Price History & Performance

Summary of share price highs, lows and changes for Veradermics
Historical stock prices
Current Share Price	US$38.48
52 Week High	US$40.11
52 Week Low	US$32.00
Beta	0
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	1.93%

Recent updates

Shareholder Returns

	MANE	US Pharmaceuticals	US Market
7D	n/a	4.6%	-0.07%
1Y	n/a	29.0%	13.9%

Return vs Industry: Insufficient data to determine how MANE performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how MANE performed against the US Market.

Price Volatility

Is MANE's price volatile compared to industry and market?
MANE volatility
MANE Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	9.7%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.3%
10% least volatile stocks in US Market	3.0%

Stable Share Price: MANE's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine MANE's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2019	19	Reid Waldman	www.veradermics.com

Veradermics, Incorporated operates as a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy.

Veradermics, Incorporated Fundamentals Summary

How do Veradermics's earnings and revenue compare to its market cap?
MANE fundamental statistics
Market cap	US$1.44b
Earnings (TTM)	-US$61.64m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-23.3x

P/E Ratio

Is MANE overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MANE income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$61.64m
Earnings	-US$61.64m

Last Reported Earnings

Sep 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-1.65
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did MANE perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/02/09 04:45
End of Day Share Price	2026/02/06 00:00
Earnings	2025/09/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Veradermics, Incorporated is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Veradermics, IncorporatedNYSE:MANE Stock Report